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Abstract: Preoperative anemia affects 30–40% of patients undergoing major surgery and is an indepen-
dent risk factor for perioperative blood transfusion, morbidity, and mortality. Absolute or functional
iron deficiency is its leading cause. Nonanemic hematinic deficiencies are also prevalent and may hamper
preoperative hemoglobin optimization and/or recovery from postoperative anemia. As modifiable risk
factors, anemia and hematinic deficiencies should be detected and corrected prior to major surgical pro-
cedures. Postoperative anemia is even more common (up to 80–90%) due to surgery-associated blood
loss, inflammation-induced blunted erythropoiesis, and/or preexisting anemia. Preoperative oral iron
may have a role in mild-to-moderate anemia, provided there is sufficient time (6–8 weeks) and adequate
tolerance of oral preparations. Postoperative oral iron is of little value and rife with gastrointestinal
adverse events. Intravenous iron should preferentially be used in cases of moderate-to-severe iron defi-
ciency anemia, concomitant use of erythropoiesis-stimulating agents, short time to surgery or nonelective
procedures, and for postoperative anemia management. Minor infusion reactions to intravenous iron are
rare, the incidence of severe anaphylactic reactions is extremely low, and there is no increase in infections
with intravenous iron. Currently available intravenous iron formulations allowing administration of large
single doses are preferred.
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Abstract
Preoperative anemia affects 30–40% of patients undergoing 
major surgery and is an independent risk factor for periop-
erative blood transfusion, morbidity, and mortality. Absolute 
or functional iron deficiency is its leading cause. Nonanemic 
hematinic deficiencies are also prevalent and may hamper 
preoperative hemoglobin optimization and/or recovery 
from postoperative anemia. As modifiable risk factors, ane-
mia and hematinic deficiencies should be detected and cor-
rected prior to major surgical procedures. Postoperative 
anemia is even more common (up to 80–90%) due to sur-
gery-associated blood loss, inflammation-induced blunted 
erythropoiesis, and/or preexisting anemia. Preoperative oral 
iron may have a role in mild-to-moderate anemia, provided 
there is sufficient time (6–8 weeks) and adequate tolerance 
of oral preparations. Postoperative oral iron is of little value 
and rife with gastrointestinal adverse events. Intravenous 
iron should preferentially be used in cases of moderate-to-
severe iron deficiency anemia, concomitant use of erythro-
poiesis-stimulating agents, short time to surgery or nonelec-
tive procedures, and for postoperative anemia manage-
ment. Minor infusion reactions to intravenous iron are rare, 
the incidence of severe anaphylactic reactions is extremely 
low, and there is no increase in infections with intravenous 
iron. Currently available intravenous iron formulations al-
lowing administration of large single doses are preferred.
© 2019 S. Karger AG, Basel
Introduction
In daily clinical practice, the presence of anemia and 
its severity are defined according to the hemoglobin (Hb) 
thresholds established by the World Health Organization 
(WHO) [1]. In the case of iron deficiency (ID) anemia 
(IDA), the WHO noted that “mild” is a misnomer, as ID 
is already advanced by the time anemia is detected and 
induces health consequences even when anemia is not 
clinically apparent [1]. 
Using WHO criteria, in 2010, one-third of the global 
population was anemic (over 2 billion people), and IDA 
remains the most common type of anemia worldwide ac-
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counting for about one-half of the total anemia burden [2]. 
Increased iron demands, reduced absorption, and/or in-
creased losses are the main causes of IDA. In a systematic 
analysis for the Global Burden of Disease Study 2016, IDA 
was the fourth leading cause of years lived with disability, 
especially in women, thus highlighting prevention and 
treatment of ID and IDA as a major public health goal [3]. 
Prevalence and Consequences of Perioperative 
Anemia
The WHO criteria for the definition of anemia may 
not be reliable for the classification of nonpregnant wom-
en undergoing surgical procedures with expected moder-
ate-to-high blood loss [4, 5]. Recently, a study of 1,388 
women who underwent cardiac surgery revealed that 
“borderline” Hb concentrations (12.0–12.9 g/dL) were 
associated with increased red blood cell transfusion 
(RBCT) requirements and prolonged hospital stay com-
pared to no anemia (Hb ≥13 g/dL) [6]. Irrespective of 
gender, in patients scheduled for a major surgical proce-
dure, a preoperative Hb < 13 g/dL should be considered 
as suboptimal [4, 5].
In a large cohort of major elective procedures (n = 
3,342), overall prevalence of anemia (Hb < 13 g/dL) was 
36%, with differences between genders (53% in women, 
23% in men; p < 0.001) and procedures (gynecologic sur-
gery, 64%; colorectal cancer, 58%; cardiac surgery, 40%; 
liver metastasis resection, 37%; elective orthopedic sur-
gery, 26%; and radical prostatectomy, 8%) [7]. Over 70% 
of anemic patients presented with ID or functional ID 
(FID), resulting in iron-restricted erythropoiesis (IRE) 
[7]. As for nonelective procedures, up to 75% of patients 
undergoing hip fracture repair surgery (n = 1,004) pre-
sented with Hb < 13 g/dL on admission [8].
A meta-analysis including almost 950,000 noncardiac 
surgical procedures reported that preoperative anemia 
was linked to an increased risk of perioperative transfu-
sion, morbidity (acute myocardial infarction, ischemic 
stroke, or kidney injury), and hospital and 30-day mortal-
ity [9]. In cardiac surgical procedures, preoperative ane-
mia has also been shown to synergize with the negative 
effects of major blood loss and RBCT on mortality risk 
[10].
Preoperative hematinic deficiencies without anemia 
should also be considered. The emerging evidence that 
nonanemic ID is a disease in its own right that deserves 
attention because of the risk it poses for patients includ-
ing the surgical population. In the above-mentioned 
study [7], 42% of nonanemic patients presented with ID 
or FID and 27% with low iron stores (as defined by pre-
operative ferritin < 100 ng/mL) [7]. Vitamin B12 deficien-
cy (defined as serum concentration < 270 pg/mL) or folate 
deficiency (defined as serum concentration < 3 ng/mL) 
are less frequent (≈10%), but they should also be repleted 
in cases of deficiency [7]. These deficiencies may hamper 
preoperative Hb optimization and/or the recovery from 
postoperative anemia as well as increase postoperative 
morbidity. In 100 consecutive cardiac procedures, preop-
erative ID was frequent (37%), and it was associated with 
preoperative anemia, higher RBCT requirements, and 
postoperative fatigue [11]. In a retrospective cohort of 
277 cardiac surgeries, prevalence of ID was 39%, and uni-
variate analysis suggested that ID was associated with a 
longer hospital stay and fewer days alive out of hospital 
on postoperative day 90 [12]. In a retrospective cohort of 
115 total hip arthroplasties at the first author’s center, pa-
tients with ID (n = 54: 45 ID, 9 FID) have lower periop-
erative Hb, higher prevalence of preoperative anemia, 
higher RBCT rate, without differences in pretransfusion 
Hb, and a trend to longer hospital stays than those with-
out ID [unpubl. data]. 
The prevalence of postoperative anemia after major 
surgery is even higher (up to 80–90%), although it varies 
widely according to different definitions underlying 
medical conditions and the type of surgery performed 
[13]. Preoperative anemia, female gender, smaller body 
surface area, perioperative blood loss, and postoperative 
blunted erythropoiesis are the main factors contributing 
to postoperative anemia [14]. There are limited published 
data extant on the consequences of postoperative anemia 
in the recovery phase from surgery, but an association 
with poorer outcomes (prolonged recovery, early postop-
erative myocardial infarction, increased mortality, and 
likelihood of readmission) has been suggested [14]. 
Therefore, as modifiable risk factors, the presence of 
preoperative anemia (Hb < 13 g/dL for both genders) and 
hematinic deficiencies should be investigated prior to 
surgery, with expected moderate-to-high blood loss 
(> 500 mL), as early as possible and ideally as soon as the 
decision to undergo surgery is made, but at least 4 weeks 
prior the scheduled procedure (“orthodox approach”) 
[5]. For elective procedures, this may lead to the post-
ponement of surgery with the intent of anemia treatment 
with the goal of resolution [5]. For nonelective proce-
dures, any available time should be used to initiate treat-
ment, which ultimately can be started or continued in the 
postoperative period [5, 14]. It is recommended es-
tablishing a patient blood management expert group in 
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every hospital performing major surgical procedures, 
where a clear perioperative anemia management pathway 
should be in place (Fig. 1, 2) [5, 14].
Although level-one evidence for ID treatment in other 
conditions is established, the lack of such evidence for 
improved outcomes in the surgical population should not 
deter one from following good clinical practice, with the 
recommendation to diagnose and treat ID with or with-
out anemia especially in those undergoing major surgery. 
Optimization of erythropoiesis is a fundamental pillar of 
patient blood management that improves patient out-
comes [8, 15].
Treatment Options for Iron Deficiency
Until newer tests to determine iron need are validated 
(e.g., reticulocyte Hb content, hypochromic red blood 
cells, or soluble transferrin receptors), the transferrin sat-
uration remains the most reliable tool to determine the 
need for iron [5, 16, 17] (Fig. 3). The appropriate combi-
nation of different laboratory tests within an integrated 
algorithm will help to establish a correct diagnosis, avoid-
ing the need for patients to return for another blood test 
and eliminating unnecessary laboratory studies [16, 17].
Following the diagnosis of ID, it is especially relevant 
to find and address the underlying cause, especially in 
unexplained and/or recurrent anemia, as well as to choose 
the appropriate therapeutic option that safely meets the 
patient’s needs. ID should be treated with oral iron or in-
travenous iron, with or without recombinant human 
erythropoietin (rHuEPO), depending on the patient’s Hb 
levels, anemia tolerance, and comorbidities, and not by 
resorting to RBCT. When pharmacologically treating 
preoperative anemia, the target Hb concentration should 
be ≥13 g/dL (in both genders) to minimize the risk of 
RBCT-associated unfavorable outcomes [5].
Oral Iron Supplementation
The National Institute for Health and Care Excellence 
in the UK (NICE) recommends offering oral iron before or 
after surgery to patients with IDA [18]. Bioavailability of 
oral iron supplements given as ferrous or ferric salts is low 
and may be further decreased by proton pump inhibitors, 
antacids, meals, and inflammation [19, 20]. Gastrointesti-






























Fig. 1. A pathway for preoperative anemia 
management [adapted from reference 5].
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supplementation [19, 20]. Low single daily (< 60 mg) [21] 
and/or alternate-day doses (< 100 mg) may reduce side ef-
fects and maximize fractional absorption [22]. In elderly 
IDA patients, a 2-month course of 50 mg of elemental iron 
daily was as effective as 150 mg daily at improving Hb and 
ferritin but with fewer gastrointestinal side effects [23]. In 
primary hip replacement, a retrospective study showed 
that, compared to no iron supplementation, liposome-en-
capsulated ferric pyrophosphate iron (30 mg/day for 3–4 
weeks preoperatively) was well tolerated, reduced transfu-
sion requirements and length of hospital stay, and resulted 
in higher Hb levels 30 days after discharge [24].
As oral iron supplementation requires a significant 
amount of time, when the interval before surgery is suffi-
cient (at least 6–8 weeks) and no contraindications are 
present, supplementation with oral iron and nutritional 
advice may be appropriate for mild-to-moderate IDA and/
or nonanemic ID or insufficient iron stores [5]. This could 
be attempted while the patient is on the surgical waiting 
list, but it is rarely practiced, and Hb incremental rises are 
slow and poor (< 1 g/dL) [25–27] (Fig. 4) (see online suppl. 
Tables 1 and 2; for all online suppl. material, see www. 
karger.com/doi/10.1159/000496965). Confirmatory ran-
domized controlled trials (RCTs) on the beneficial effects 
of preoperative oral iron supplementation are warranted.
As for postoperative oral iron, a review of 7 RCTs, in-
cluding 804 orthopedic and cardiac surgery patients, 
showed that high-dose oral iron therapy (100–300 mg el-
emental iron/day) was not better than placebo in correct-
ing postoperative anemia and/or reducing transfusion re-
quirements, and was associated with significant gastroin-
testinal side effects [14] (see online suppl. Table 3). The 
vast majority of these studies did not include patients with 
preoperative anemia and/or iron deficiency, or confirmed 
Major elective or nonelective surgery





Consider intravenous iron supplements





















Fig. 2. A pathway for postoperative anemia 
management [adapted from reference 14]. 
Hb, hemoglobin; ID, iron deficiency; Post-
OP, postoperative; RBCT, red blood cell 
transfusion.
✔ Iron repletion
  Ferritin >100 ng/mL plus transferrin saturation >20%
✔ Absolute iron deficiency
  Ferritin <30 ng/mL
  Ferritin 30–100 ng/mL plus transferrin
  saturation <20% and/or C-reactive protein >5 mg/L
✔ Iron sequestration
  Ferritin >100 ng/mL plus transferrin saturation <20%
  and/or C-reactive protein >5 mg/L*
✔ Low iron stores
  Ferritin 30–100 ng/mL** plus transferrin saturation >20%
Fig. 3. Iron status definitions. * More specific tests may be needed 
(e.g., reticulocyte hemoglobin content, hypochromic red blood 
cells, serum transferrin receptors) to confirm iron deficiency. 
** For surgeries with expected hemoglobin drop > 3–4 g/dL due to 
bleeding; 1 ng/mL ferritin ≈8 mg stored iron [adapted from refer-
ences 5, 16, 19].
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postoperative iron deficiency; i.e., those who potentially 
could benefit the most from iron supplementation. 
Even in the presence of ID, it is unlikely that postop-
erative administration of oral iron salts is effective in cor-
recting anemia since the high levels of hepcidin, induced 
by surgical stress-associated inflammation, would inhibit 
intestinal absorption of oral iron [14, 28]. The results of 
the IRONOUT study in patients with chronic heart fail-
ure and ID seem to support the ineffectiveness of oral iron 
salts in the setting of inflammation [29].
Intravenous Iron Supplementation
In cases of intolerance to or ineffectiveness of iron salt, 
switching to intravenous iron may be appropriate [19]. In 
surgical patients, the intravenous route is preferred in 
cases of moderate-to-severe anemia, ongoing blood loss, 
inflammatory status, use of erythropoiesis-stimulating 
agents, short time to surgery, or nonelective procedures 
[5]. Intravenous iron should also be preferred for man-
agement of moderate-to-severe postoperative anemia 
(Hb < 10 g/dL), especially in patients with low preopera-
tive iron stores [14]. As the response to intravenous iron 
is not immediate, not all postoperative RBCT could be 
avoided, but correction of ID and amelioration of anemia 
could improve patient performance [30]. 
The vast majority of published studies, especially in 
orthopedic and colorectal cancer surgery, support the 
preferential used of intravenous over oral iron for treat-
ing perioperative anemia (see online suppl. Tables 1, 2, 
and 4). In cardiac surgery, conflicting results have been 
found depending on whether intravenous iron was given 
with or without concomitant rHuEPO [31, 32]. Most 
guidelines from professional associations and interna-
tional consensus documents recommend the administra-
tion of intravenous iron for the management of periop-
erative anemia [5, 14, 33–35].
Orthopedic clinic


























Vitamin B12: 1 × 1 mg s.c.
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25 i.v. iron (2%)
1,145 no treatment
Fig. 4. Two clinical protocols for preoperative anemia management [data taken from 45 (protocol I) and 27 (pro-
tocol II)]. FCM, ferric carboxymatose; Ft, ferritin; Hb, hemoglobin; ID, iron deficiency; PBM, patient blood man-
agement; rHuEPO, recombinant human erythropoietin; THA, total hip arthroplasty; TKA, total knee arthro-
plasty.
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Different intravenous iron formulations are commer-
cially available for clinical use. These include ferric gluco-
nate, iron sucrose, low-molecular-weight iron dextran, 
ferric carboxymaltose (FCM), ferumoxytol, or iron iso-
maltoside 1000. All of these formulations have been 
shown to have a dose-dependent efficacy for correcting 
ID [19, 36]. Intravenous iron formulations are increas-
ingly safer, though they are more expensive than oral 
iron, and there is a need for venous access and monitor-
ing. While uncommon, minor infusion reactions, con-
sisting of pressure in the chest or back, or flushing, resolve 
without intervention and should not be misconstrued or 
treated as anaphylaxis. Based on the preponderance of 
published evidence, it is inappropriate to intervene with 
vasopressors and/or antihistamines, which are responsi-
ble for virtually all serious adverse events ostensibly at-
tributed to intravenous iron [37]. The incidence of severe 
anaphylactic reactions is extremely low (≈1 in 250,000 
administrations), but it should not be overlooked [38]. As 
with the administration of any intravenous medication, 
practitioners should be prepared to manage serious acute 
hypersensitivity with standard measures, not specific to 
intravenous iron. The European Medicines Agency stated 
that “IV iron products should be administered only when 
staff trained to evaluate and manage anaphylactic reac-
tions, as well as resuscitation facilities, are immediately 
available” [39]. An algorithm for scaling the intensity of 
treatment of hypersensitivity reactions during intrave-
nous iron infusion to the clinical picture and/or response 
to therapy has been recently published [38]. Other non-
evidence-based concerns regarding intravenous iron 
supplementation in surgical patients, such as increased 
risk of infection, iron overload, or oxidative stress, have 
also been refuted [19, 33, 40]. FCM is associated with a 
high incidence of moderate-to-severe hypophosphate-
mia, which may persist for weeks or months [41, 42] [for 
a complete discussion on the safety of iron supplementa-
tion, see the article by DeLoughery et al. in this issue].
Of note, intravenous iron formulations which allow 
short-time (15–60 min) infusion of high iron doses (1,000 
mg or more), such as low-molecular-weight iron dextran, 
FCM, isomaltoside 1000, or ferumoxytol, are preferred by 
both physicians and patients compared to ferric gluco-
nate or iron sucrose [19, 36].
Recombinant Human Erythropoietin 
The administration of rHuEPO should be considered 
for patients with anemia of chronic inflammation and no 
contraindications to rHuEPO in addition to treating the 
underlying disease [43–47]. Elderly patients with anemia 
of unknown etiology, kidney diseases, or mild/moderate 
myelodysplastic syndrome often have good responses to 
rHuEPO administration, although adequate iron supple-
mentation should always be ensured, preferably via the 
intravenous route [16].
In Europe, rHuEPO is licensed for improving preopera-
tive Hb levels and reducing RBCT rates in patients under-
going elective orthopedic surgery with Hb between 10 and 
13 g/dL and expected to have moderate blood loss. In a re-
cent meta-analysis (7 RCTs, 1,221 knee or hip arthroplas-
ties), compared to a control group (placebo or no treat-
ment), preoperative rHuEPO administration (generally, 
3–4 × 40,000 IU) resulted in lower RBCT rates (odds ratio 
[OR] = 0.41; 96% confidence interval [CI] = 0.28–0.60; p = 
0.0001) and less units transfused (OR = –0.45; 95% CI = 
–0.68 to –21; p = 0.0002), while Hb levels were higher at all 
perioperative time points (day of surgery and 24–48 h and 
3–5 days postoperatively, or at discharge) [43]. 
Several observational studies and a recent RCT have 
also reported on the beneficial effects of fewer rHuEPO 
doses in orthopedic patients, especially when combined 
with intravenous iron within a patient blood management 
program [25, 27, 44, 45] (see online suppl. Table 2). Theu-
singer et al. [45] reported on the results of a “pragmatic ap-
proach” for patients presenting to the anesthesiologist at 
least 4 weeks prior to major orthopedic surgery (n = 1,985). 
Those with anemia (Hb < 13 g/dL; n = 178) received FCM 
(1,000 mg i.v.), rHuEPO (40,000 IU s.c.) and vitamin B12 
(1 mg s.c.), plus oral folic acid (5 mg/day for 4 weeks) and 
were reassessed 14 days later. If Hb remained < 13 g/dL, 
they received an additional dose of FCM (1,000 mg), rHu-
EPO (40,000 IU), and vitamin B12 (1 mg) (n = 27). All 
treated patients presented with normal Hb levels (≥13 g/
dL) on the day of surgery. These results favorably com-
pared with those reported by Petis et al. [27] on 2,088 pa-
tients scheduled for lower limb arthroplasties, of whom 
57% received oral iron between surgery indication and 
preoperative assessment. Additionally, 132 received rHu-
EPO (40,000 IU, 1–4 doses) and 42 intravenous iron su-
crose (300 mg) between preoperative assessment and the 
day of surgery, when 16% were still anemic. The lower 
intravenous iron dose might have accounted for the dif-
ference in anemia prevalence on the day of surgery com-
pared to the study by Theusinger et al. [45] (Fig. 3).
The possible role of off-label use of rHuEPO in cardiac 
and gastrointestinal cancer surgery has also been explored. 
In cardiac surgery, preoperative administration of rHu-
EPO, with or without intravenous iron, significantly in-
creased preoperative Hb levels, reduced RBCT require-
ments, and/or decreased postoperative major complica-
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tions and length of stay when compared to a control group 
[31, 46, 47]. In gastrointestinal cancer, a pooled-data analy-
sis (6 RCTs, 621 patients) showed that perioperative treat-
ment with rHuEPO did not reduce RBCT rate (33 vs. 37%; 
OR: 0.89; p = 0.206) [48]. The increasing use of rHuEPO in 
oncologic surgery (due to short-term use and positive Hb 
response) is also supported by the lack of convincing evi-
dence on rHuEPO affecting cancer-related mortality or dis-
ease progression [49, 50]. The administration of rHuEPO is 
still off label for patients undergoing potentially curative 
cancer surgery [51]. A benefit in RBCT rate reduction has 
been observed in most studies in which very short-term 
perioperative rHuEPO, with or without intravenous iron, 
was administered to patients undergoing lower limb ar-
throplasty, hip fracture repair, or cardiac surgery (“oppor-
tunity approach”) (see online suppl. Table 5). However, 
some guidelines do not support the off-label use of this 
agent [18]. A call for reevaluation of some of the persistent 
misconceptions of rHuEPO use based on current off-label 
use and improved Hb levels and RBCT reduction has yet to 
generate changes in labeling or restriction, although in the 
US, the Federal Drug Administration has relaxed some of 
the risk mitigation requirements of the use of rHuEPO.
Red Blood Cell Transfusion
RBCT should be restricted to those with severe IDA, 
poor physiological reserve, and/or acute symptoms re-
quiring immediate correction, using the minimal amount 
necessary to achieve clinical stability. In surgical patients, 
RBCT is associated with increased risk of infection, circu-
latory overload, thromboembolic events, prolonged hos-
pitalization, impaired quality of life, cancer recurrence, 
and mortality, and should be minimized or avoided [52–
57]. A restrictive RBCT policy and transfusing 1 RBC unit 
at a time, with post-RBCT reassessment, are strongly rec-
ommended by most guidelines [5, 14, 18, 32–35, 58].
A critical literature review showed that patient-adapt-
ed, restrictive transfusion criteria are safe and effective in 
reducing both RBCT rates and RBCT volumes [59]. Most 
of these RCTs presented some serious drawbacks: (1) in-
clusion of a selected patient population, with strict inclu-
sion and exclusion criteria, which may preclude a general 
applicability of results; (2) decisions on RBCT are made 
almost exclusively on the basis of a predefined transfusion 
threshold; and, most important, (3) no other anemia treat-
ments are applied, and patients commonly maintained 
low Hb levels during hospitalization and at discharge.
In most but not all cases, RBCT produces a rapid, albeit 
transient, rise in Hb that increases oxygen-carrying capac-
ity and alleviates anemia symptoms. Severe IDA will recur 
unless the underlying cause is identified and addressed 
when possible. After stability has been achieved with RBCT, 
additional pharmacological treatment should be consid-
ered (e.g., intravenous iron, rHuEPO) [14, 60, 61].
Recommendations
• In every hospital performing major surgical proce-
dures, a clear perioperative anemia management path-
way should be implemented.
• In major surgery, a preoperative Hb < 13 g/dL should 
be considered suboptimal in men and women, and re-
quires to be improved prior to the procedure.
• Preoperative anemia should be detected, diagnosed, 
and properly treated prior to major surgery. For elec-
tive procedures, this may need the postponement of 
surgery with the intent of anemia treatment with the 
goal of resolution.
• Iron deficiency without anemia should be treated to 
optimize preoperative iron stores and hasten the re-
covery from postoperative anemia.
• When prescribing oral iron, consider low single doses 
(< 100 mg) on alternate days to improve absorption 
and tolerability.
• In case of immediate surgery or postoperative anemia, 
the vast majority of published studies support the pref-
erential use of intravenous iron over oral iron, and in-
travenous iron formulations which allow short-time 
infusion (15–60 min) of high iron doses ( ≥1,000 mg) 
are generally preferred.
• Consider rHuEPO (1–2 × 40,000 IU) with intravenous 
iron for patients with Hb < 13 g/dL and inflammation 
or not adequately responding to intravenous iron if no 
contraindications are present, and provide adequate 
pharmacological thromboembolic prophylaxis. 
• When pretreatment Hb is low, it would be advisable to 
check the response to anemia therapy after 2 weeks, 
and all treated patients should have an Hb assessment 
on the day of surgery.
• RBCT should be restricted to those with severe IDA, 
poor physiological reserve, and/or acute symptoms re-
quiring immediate correction, using the minimal 
amount necessary to achieve clinical stability, and fol-
lowed by pharmacological anemia treatment.
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